drugset / Trial / NCT07057622

A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs

NCT07057622

Phase 3 Recruiting 184 enrolled HTA Co., Ltd.
RandomizedParallel-groupOpen-labelOther

Summary

The study is to evaluate the sstr antagonists, 68Ga-DOTATATE and 177Lu-DOTATATE,as a pair of diagnostic/therapeuticradiopharmaceuticals(theranostics)in patients with NETS

Timeline

Start
2023-12-12
Primary completion
2026-11-24
Completion
2027-02-24

Drugs

EvaluationDrugModalityDoseRoute
Subject 177Lu-DOTATATE Peptide 7400 mbq
Comparator Octreotide Peptide 60 mg

Indications

No indication recorded.